Differences in Airway Cytokine Profile in Severe Asthma Compared to Moderate Asthma*

Size: px
Start display at page:

Download "Differences in Airway Cytokine Profile in Severe Asthma Compared to Moderate Asthma*"

Transcription

1 Original Research ASTHMA Differences in Airway Cytokine Profile in Severe Compared to Moderate * Joanne Shannon, MD; Pierre Ernst, MD; Yasuhiro Yamauchi, MD; Ronald Olivenstein, MD; Catherine Lemiere, MD; Susan Foley, MD; Leo Cicora, RT; Mara Ludwig, MD; Qutayba Hamid, MD, PhD; and James G. Martin, MD, DSc Background: Some studies of severe asthma suggest that persistence or alteration in the pattern of inflammation may be associated with the severity of the disease. Whether there are differences in the expression of the principal cytokines and chemokines relevant to eosinophilic and neutrophilic inflammation in the airway tissues of severe compared to moderate asthmatics has not been determined. The aim of this study was to compare the patterns of expression of representative T-helper (Th) type 1 (interferon [IFN]- ) and Th-2 cytokines (interleukin [IL]-4, IL-5) and the neutrophil- and eosinophil-associated chemokines (IL-8 and eotaxin) in the airway tissues of patients with severe and moderate asthma. Methods: Subjects with severe asthma (n 24) and a comparison moderate asthma group (n 26) were assessed using spirometry, induced sputum, exhaled nitric oxide, and bronchial biopsy. The expression of proteins of interest in the epithelium and subepithelium of the airway wall was examined by immunocytochemistry. Results: Subjects with severe asthma were more symptomatic, had a lower FEV 1, and had more sputum neutrophilia (p 0.007) and eosinophilia (p 0.001). Exhaled nitric oxide was similar between groups. IL-8 and IFN- expression were increased and IL-4 expression was decreased in severe asthma compared to moderate disease (p < for each comparison). Eotaxin and IL-5 expression did not differ between the groups. Conclusion: Patients with severe asthma have increases in neutrophils and eosinophils in the sputum, and differ in airway cytokine/chemokine expression from moderate asthmatics. Excess neutrophilia may be explained by increased expression of IL-8, but differences in eosinophilia do not appear to be associated with IL-5 and eotaxin expression. (CHEST 2008; 133: ) Key words: cytokines; immunology; inflammation Abbreviations: ATS American Thoracic Society; BMI body mass index; IFN interferon; IL interleukin; MBP major basic protein; Th T-helper Severe asthma affects only a small proportion of patients with asthma, but it is responsible for an substantial proportion of the morbidity and costs related to treating this condition. 1,2 Severe or treatment-resistant asthma is likely a heterogeneous condition, and multiple factors have been proposed to explain the difficulty in managing these patients. These factors include poor compliance with treatment, lack of recognition of associated conditions, or true biological resistance to therapy. 3 Distinct patterns of airway remodeling 4 and inflammatory marker profiles 5 have emerged as important areas of investigation in the attempt to better understand and define severe asthma. tic airway inflammation is associated with an exuberant T-helper (Th) type 2 immune response that results in sputum and tissue eosinophilia. These processes are usually responsive to treatment with corticosteroids. 6 However, some asthmatic patients are resistant to usual doses of steroids by mechanisms that have been extensively studied. 7 9 One of the principal causes appears to be a failure to 420 Original Research

2 suppress T-cell cytokines such as interleukin (IL)-2, IL-4, and IL-5. It is therefore reasonable to anticipate that the inflammatory process in severe asthmatics might show a different pattern of cytokines to well-controlled moderate asthmatics. In order to address this issue, we recruited patients with severe asthma and a comparison group with moderate asthma and compared their clinical characteristics and several biomarkers, including induced-sputum inflammatory cells and exhaled nitric oxide. Furthermore, those subjects who consented underwent bronchoscopy, and bronchial biopsy specimens were obtained to compare prototypical Th-1 and Th-2 cytokines and neutrophil- or eosinophil-associated chemokines in the airway walls in order to help elucidate differences in the pattern of inflammation associated with severe asthma. We chose patients with moderate persistent asthma, well controlled on usual maintenance therapy, as a comparison group in order to limit the extent to which the results may be confounded by treatment. Both groups were treated with inhaled corticosteroids. The data were presented in abstract form at the Annual Meeting of the American Thoracic Society (ATS), May Study Subjects Materials and Methods Physicians at two tertiary care centers were asked to identify patients with severe asthma who met the following criteria proposed by the ATS workshop on refractory asthma. 10 For severe asthma, subjects were required to have received treatment with daily oral steroids for 50% of the previous 12 months or to have been prescribed high-dose inhaled-steroid equivalent to 880 g/d of fluticasone, (ex-actuator) with at least one other add-on therapy (long acting -agonist, leukotriene receptor antagonist, or theophylline) continuously over the prior 12 *From Montreal Chest Institute (Drs. Shannon, Ernst, and Olivenstein), Respiratory Division of the McGill University Health Centre; Meakins-Christie Laboratories (Drs. Yamauchi, Foley, Ludwig, Hamid, Martin, and Mr. Cicora), McGill University; and Respiratory Division (Dr. Lemiere), Hôpital Sacré- Coeur, Montreal, QC, Canada. Dr. Ernst and Dr. Martin have received an unrestricted grant from GlaxoSmithKline that was in part used to support this project. None of the other authors have any conflicts of interest to declare. Manuscript received January 30, 2007; revision accepted October 26, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). This study and the Difficult Program are supported by the Richard and Edith Strauss Canada Foundation and an unrestricted grant from GlaxoSmithKline, Canada. Joanne Shannon was the recipient of the Ann Woolcock Memorial Fellowship financed by GlaxoSmithKline, Canada. Correspondence to: James G. Martin, MD, DSc, Meakins Christie Laboratories, McGill University, 3626 St. Urbain, Montreal, QC, Canada H2X 2P2; James.martin@mcgill.ca DOI: /chest months (major criteria), as well as fulfilling at least two of the following six minor criteria: need for daily short-acting -agonist; persistent airflow obstruction (prebronchodilator FEV 1 80% and FEV 1 /FVC 70% of predicted); one or more urgent-care visits in the last 12 months; three or more steroid bursts in the last 12 months; prompt deterioration with 25% dose reduction of oral corticosteroids; or near-fatal asthma event in the last 3 years. For comparison, we recruited a group of patients with moderate asthma by asking clinicians who had referred patients with severe asthma to identify subjects of similar age and gender distribution whose asthma was persistent but not severe according to the following criteria: asthma controlled on a minimum of 176 g/d of fluticasone (or equivalent) and not 880 g/d of fluticasone (or equivalent) with or without concomitant therapy with a long-acting -agonist, long-acting -agonist leukotriene receptor antagonist, or theophylline; no more than two steroid bursts in the past year, and none in the past 3 months with total days on oral steroids 30 days in the prior 12 months; FEV 1 70% of predicted and 90% of personal best from the past 2 years; and a maximum of one unscheduled visit for asthma in the prior 12 months. All subjects met ATS criteria for the diagnosis of asthma, were between the ages of 18 and 69 years, were not current smokers (ex-smokers who had quit for at least a year were included), did not have any other known pulmonary disease including COPD, and had no major comorbid diseases such as HIV infection, cancer, or congestive heart failure. The study was approved by the research ethics committee of each participating center. All subjects gave their written consent. Study Procedures Subjects recruited with severe asthma underwent a 1-month run-in period for the assessment of compliance. These subjects were provided with a combination metered-dose inhaler containing fluticasone, 250 g, and salmeterol, 25 g, in each inhalation, and were instructed to take two inhalations bid. An electronic device (MDILog; Medtrac Technologies; Lakewood, CO) was attached to each subject to accurately monitor use. 11 We included only subjects who inhaled at least the four inhalations prescribed per day on at least 70% of days. This criterion led to the exclusion of 25% of subjects, approximately. Furthermore, subjects with severe asthma underwent evaluation and coaching by a certified asthma educator for the assessment of inhaler technique and environmental control measures. The current report pertains to 24 patients with severe asthma and 26 patients with moderate asthma who agreed to undergo bronchoscopy and from whom adequate bronchial biopsy specimens were obtained. Tissues from some of the subjects have been used for the comparison of sputum and tissue neutrophilia and eosinophilia, and have formed the basis of a separate report. 12 Study subjects completed the Control Questionnaire as described by Juniper and colleagues. 13 Spirometry was performed according to ATS recommendations. 14 Exhaled nitric oxide analysis was performed according to ATS guidelines. 15 An expiratory flow rate between L/s and L/s was used during collection of exhaled gas. Sputum induction was initiated using aerosolized normal saline solution. If well tolerated, hypertonic saline solution was used at increasing concentrations (3%, 4%, and 5%) delivered by an ultrasonic nebulizer, as described by Pin et al. 16 After each period of inhalation, FEV 1 was measured for safety. Each subject was asked to blow his nose, rinse his mouth, and swallow the water to minimize contamination with postnasal drip and saliva. Subjects were instructed to cough into a sterile container, and the expectorated sputum was processed within 2 h. The samples were processed as described previously. 17 Cytospins were prepared (Shandon Somerset; Cheshire, UK) on CHEST / 133 / 2/ FEBRUARY,

3 poly-l-lysine coated slides and fixed using acetone/methanol (60:40) for 7 min followed by air drying. A sample was considered adequate if the slides showed 20% squamous epithelial cells. The cytospins were immunostained for major basic protein (MBP) and neutrophil elastase using the alkaline phosphatase anti-alkaline phosphatase method and monoclonal primary antibodies for MBP (a generous gift from Dr. R. Moqbel, University of Alberta, Edmonton, AB, Canada) and elastase (DakoCytomation; Mississauga, ON, Canada). Bronchoscopy was performed under light sedation with midazolam. Endoscopic bronchial biopsy samples were obtained from various segmental and subsegmental carinae of the right lung (Olympus Biopsy Forceps 35C; Olympus Medical Systems Corporation; Tokyo, Japan), fixed in formaldehyde and embedded in paraffin prior to cutting. A peroxidase-based method of staining was used as previously described 18 using 5- m sections. Immunostaining was performed using monoclonal antibodies for IL-4, IL-5, interferon (IFN)-, IL-8, and eotaxin (R&D Systems; Minneapolis, MN). Mouse IgG 1 served as the isotype control for IL-4, IL-5, IL-8, and eotaxin, while mouse IgG 2 A was the isotype control for IFN-. StreptABComplex/HRP and DAB substrate (DakoCytomation) were used to develop the reactions according to manufacturer guidelines. Slides were examined and images acquired by a BX51 Olympus microscope attached to a Cool- SNAP-Pro color digital camera (Carsen Group; Markham, ON, Canada) using Image Pro-plus 4.0 (Media Cybernetics; Silver Spring, MD). Scoring of epithelial staining for IL-8 and eotaxin, based on the percentage of the epithelium that stained positively, was performed as follows: 0 no staining, 1 0 to 12.5%, to 25%, 3 25 to 37.5%, to 50%, 5 50 to 62.5%, to 75%, 7 75 to 87.5%, and to 100%. Subepithelial immunoreactive cells are reported as the number of cells that stained positively per field with a given antibody. The analysis was performed by an observer blinded as to group status. Subjects underwent allergy skin testing to 13 common aeroallergens (Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat, dog, horse, ragweed, grass mix, tree mix, weed mix, feather mix, Alternaria, Aspergillus, Cladosporium) as well as positive (histamine, 10 mg/ml) and negative (diluent) controls (Medic-Savoure; Dutton, ON, Canada). A test result was considered positive if the larger of two perpendicular diameters was 3 mm greater than the control. Statistical Analysis Mean results of each group were compared using t tests. Medians and interquartile ranges were also calculated for continuous variables and differences between patients with moderate and severe asthma compared using the Wilcoxon rank-sum test. The results were similar to those obtained with t tests such that only these are presented. Proportions were compared by 2. Correlations were performed using the Spearman rank test, and values that were significant at p 0.01 level of significance are reported. Results Clinical Characteristics Characteristics of the 26 subjects with severe asthma and 24 subjects with moderate or treatment responsive asthma are provided in Table 1. Subjects were of similar age, and there was a trend toward a higher proportion of women in the severe group. Four subjects in each group had smoked 10 pack-years, and a similar proportion was obese as judged by a body mass index (BMI) 30 kg/m 2. Among those in whom the age of onset could be Variables determined, 18 of 21 subjects in the moderate group and 20 of 23 subjects in the severe group reported onset of symptoms or diagnosis at 12 years of age. Sixteen of 22 subjects in the severe group in whom allergy skin tests were interpretable had two or more positive reactions. Allergy skin testing was only available in 21 subjects in the moderate group, 19 of whom had two or more positive reactions to 13 common aeroallergens. As expected, the severe asthma group was more symptomatic, had a lower FEV 1, and was receiving higher doses of inhaled corticosteroids, expressed in Table 1 as micrograms of fluticasone. All subjects in the severe asthma group were receiving concomitant long-acting -agonists, and 9 of 24 subjects with treatment-resistant asthma were receiving oral corticosteroids on a regular basis. Exhaled Nitric Oxide and Sputum Analysis Expired nitric oxide was similar in the two groups: parts per billion in the severe subjects, and parts per billion in the moderate subjects. The severe group had a higher percentage of both eosinophils ( %) compared to the moderate subjects ( %; p ) and neutrophils ( % and %, respectively; p ) in their sputum. There were no significant correlations between nitric oxide and sputum eosinophils and FEV 1 ( and 0.029, respectively). However, sputum neutrophil counts showed a modest inverse correlation with FEV 1 ( 0.529; p 0.01). Tissue Biomarkers Table 1 Description of Subjects* Moderate (n 26) Severe (n 24) p Value Age, yr NS Women 10 (38) 14 (58) NS BMI 30 kg/m 2 8 (31) 7 (29) NS Smoking 10 4 (15) 4 (17) NS pack-yr Symptom score FEV 1 % predicted Inhaled corticosteroids, g/d Long-acting 2 -agonists 16 (61.5%) 24 (100%) Oral corticosteroids daily 0 9 (35.5%) *Data are presented as mean SD or No. (%). NS not significant. Sputum was available for only 25 subjects in the controlled group. We assessed the number of immunoreactive cells in the airways to assess IL-4 and IL-5 expression as representative Th-2 cytokines, whereas we assessed 422 Original Research

4 IFN- as the prototypical Th-1 cytokine. Subepithelial IL-5 expression was similar in the severe and moderate asthmatic subjects. In contrast, IL-4 expression was significantly less in the airway subepithelial compartment of subjects with severe compared to moderate asthma. Figure 1 (top, A) shows an illustrative example of IFN- expression in subepithelial cells that are predominantly inflammatory cells. Subepithelial IFN- expressing cells were present in larger numbers in the severe group than in the moderate group. There was no evidence of cytokine expression by airway smooth muscle in either group. Table 2 Biomarkers in the Airway Wall* Variables Moderate (n 26) Severe (n 24) p Value IL-8 epithelium IL-8 subepithelium Eotaxin epithelium NS Eotaxin subepithelium NS IFN- subepithelium IL-4 subepithelium IL-5 subepithelium NS *Data are presented as mean SD. Subepithelial inflammatory cells are reported as the number of cells that stained positively per field with a given antibody. See Table 1 for expansion of abbreviation. Scoring of epithelial staining for IL-8 and eotaxin (refers to the percentage of the epithelium that stained positively) was as follows: 0 no staining, 1 0 to 12.5%, to 25%, 3 25 to 37.5%, to 50%, 5 50 to 62.5%, to 75%, 7 75 to 87.5%, and to 100%. Illustrative examples of immunoreactivity for IL-8 are shown in Figure 1 (center, B, and bottom, C). IL-8 immunoreactivity was clearly seen in the epithelial and subepithelial compartments and was greater in the severe asthma subjects. Eotaxin 1 expression was not different between groups. IL-8 and eotaxin immunoreactivity was detected in airway smooth muscle in both groups, but we did not assess this tissue for possible differences in expression levels. The results of the morphometric analysis of bronchial biopsies are provided in Table 2 and in Figures 2, 3. None of the cytokines or chemokines examined showed any correlation with FEV 1. However, epithelial and subepithelial expression of IL-8 was inversely correlated with sputum eosinophilia ( and 0.479, respectively; p 0.01). Figure 1. Top, A: Photomicrograph of cells demonstrating immunoreactivity for IFN- expression in inflammatory cells in the subepithelial compartment (hematoxylin, original 200). Center, B: IL-8 expression in the airway epithelium and airway smooth muscle (insert) in a subject with severe asthma (hematoxylin, original 400). Bottom, C: The lesser degree of expression of IL-8 in a subject with moderate asthma (hematoxylin, original 200). Figure 2. Means and SEs for number of cells per field in the subepithelium of bronchial biopsy samples that stain for IFN-, IL-4, and IL-5 among patients with moderate asthma (light bars) and severe asthma (dark bars); p values are based on t tests. CHEST / 133 / 2/ FEBRUARY,

5 Figure 3. Means and SEs of scores for immunostaining of epithelium for IL-8 (left, A) and number of cells per field in the subepithelium of bronchial biopsy samples that stain for IL-8 (right, B) among patients with moderate asthma (light bars) and severe asthma (dark bars); p values are based on t tests. Discussion We studied subjects with severe poorly controlled asthma, compliant with medication, and compared them to patients whose disease was moderate and managed successfully with regular inhaled steroids in conjunction with long-acting -agonists in many instances. Despite high doses of inhaled or supplemental doses of oral corticosteroids, the patients with severe asthma had more airway inflammation as reflected in sputum eosinophilia and neutrophilia. Furthermore, these subjects expressed a chemokine (IL-8) and the cytokine (IFN- ) in their bronchial walls, which are thought of as Th-1 inflammationassociated molecules more typical of the neutrophilic inflammatory response of patients with COPD and cystic fibrosis. There was lower expression of IL-4, a typical Th-2 cytokine. Bronchial IL-5 and eotaxin expression were similar among patients in the severe and moderate groups. Sex distribution and BMI were similar between the subjects with severe and those with moderate asthma. This is in contrast to the much larger multicenter European series, 19 in which women predominated and, among women, those with severe asthma were heavier. The subjects with severe asthma in our series were symptomatic, had a low mean FEV 1, and were receiving high doses of corticosteroids. In these respects, our subjects with severe asthma are quite comparable to the group of patients with treatment-resistant asthma reported by Heaney and colleagues. 20 There was no difference in the age of onset of asthma among subjects with severe asthma as compared to moderate, responsive asthma. In this respect, our severe asthma group of subjects differed from that reported on by Miranda and colleagues 21 in that most of our subjects reported the onset of asthma after the age of 12 years. The moderate group was receiving long-acting -agonists in 61% of cases, which may mean that the group had somewhat more severe asthma than moderate asthmatics as defined by ATS criteria. However, the use of this controller medication may have reduced the observed differences between the groups and strengthens any conclusions related to observed differences in inflammation. Our series of patients has two important characteristics. Firstly, the diagnosis of asthma and the exclusion of competing diagnoses were ensured by prior evaluation and prolonged follow-up by expert physicians. Secondly, patients in the severe asthma group were objectively monitored for compliance during a 1-month period prior to being accepted into the study, thereby excluding patients whose disease severity may have resulted from inadequate therapy. The pattern of inflammation in the sputum differed between the severe asthma and moderate asthma groups. Subjects with severe asthma had a greater proportion of eosinophils and neutrophils in induced sputum than subjects with moderate, consistent with other reports 22 of persistent inflammation despite usual treatment. We did not find a subgroup without eosinophilia; the lowest sputum eosinophil count in the severe group was 2%. Im- 424 Original Research

6 munocytochemistry for the eosinophil granule MBP as opposed to usual histochemical stains of sputum may have enhanced the sensitivity of detection of low levels of eosinophilia. There were also differences in some of the important mediators of eosinophilia and neutrophilia in the airway wall biopsy findings. Notably, IL-8 expressing cells were increased, particularly in the subepithelial compartment of the airway wall, and this potent chemoattractant for neutrophils 23,24 may have accounted for the excess of neutrophils that was seen in the severe group as compared to those with more easily controlled or moderate asthma. Not surprisingly, there was an inverse relationship between sputum eosinophilia and epithelial IL-8 expression. There is increasing recognition of the association of sputum neutrophilia in the sputum with severe asthma and with virally induced exacerbations of asthma. 25,26 However, the effects of IL-8 may not be limited to actions on neutrophils. IL-8 may act on airway smooth muscle itself to cause contraction or may serve as a chemoattractant, potentially contributing to airway remodeling through promoting migration of smooth-muscle cells within the airway wall. 27 The stimuli that trigger the expression of IL-8 are not entirely clear. Endotoxin exposure and viral infection could result in increased expression of IL-8. 28,29 It seems possible that refractory asthma might be associated with persistent viral infection, as has been described in COPD. 30 IL-8 is increased also by smoking, but there were no current smokers among the patients we studied and an equal number of ex-smokers among patients with moderate and severe asthma. None of the above mechanisms is therefore likely to be pertinent to the current study. Leukotriene D 4, acting through the cysteinyl-leukotriene-1 receptor, was shown to transcriptionally regulate the synthesis of IL-8 through the transcription factors nuclear factor- B and activating protein Corticosteroids appear to favor IL-8 expression in vivo. An increase in the expression of IL-8 in the epithelium and an increase in airway neutrophils have been observed in patients receiving oral corticosteroids. 32 IL-8 was increased in both the epithelium and subepithelium of our group with severe asthma, approximately a third of whom were receiving regular oral corticosteroids as well as a significantly higher average dose of inhaled corticosteroids as compared to the moderate treatment-responsive group. However, the apparent up-regulation of IL-8 by steroids is likely to be an indirect mechanism because there is good evidence that corticosteroids directly inhibit IL-8 production by human epithelial cells in vitro. 33 Subepithelial IFN- was increased and IL-4 was decreased in patients with severe asthma as compared to the control patients with moderate asthma. This interrelationship between these two cytokines is expected as they are counter regulatory. 34 IFN- in the sputum of patients with asthma has been related to asthma severity. 35,36 The source of the IFN- in the sputum appears to be CD8 lymphocytes 35 ; however, we are not certain as to the cellular source in the airway tissues. Serum levels of IFN- have been found to relate to a greater decline in FEV 1 over time in patients with asthma. 37 The cells expressing IL-4 are also uncertain, but mast cells are a likely source. 38 One possible interpretation of the findings for the airway expression of IL-4 and IFN- is that treatment may have been adequate to suppress Th-2 inflammation to a greater extent than in moderate subjects and that other factors must then have accounted for the clinical manifestations of asthma that caused it to be more severe. IL-5 and eotaxin in the airway wall were similar in patients with severe and moderate asthma despite the fact that sputum eosinophilia was more marked in the severe group. The discrepancy is possibly due to the fact that sputum is representative of both the proximal and distal airways while endobronchial biopsies sample the proximal airways alone. It is likely that there is more distal inflammation in severe asthma compared to moderate disease. 39 It is also possible that the trafficking of eosinophils through the airway wall is increased as a result of other eosinophil chemoattractants such as leukotriene B 4, the cysteinyl leukotrienes, or 5-OXO-eicosatetranenoic acid, 40 all products of the 5-lipoxygenase pathway. As reported by others, 19 expired nitric oxide did not differentiate between subjects with moderate and severe asthma, perhaps because all subjects were receiving relatively high doses of corticosteroids. In conclusion, patients with severe treatmentrefractory asthma have a different cytokine profile in bronchial biopsy findings than a group with moderate asthma, demonstrating an increase in IL-8 and IFN- expressing cells. The expression of the principal Th-2 cytokines was not more elevated in the group with severe asthma and suggests that persistence of Th-2 inflammation does not account for differences in the severity of disease. A sample of subjects with severe asthma fulfilling the same selection criteria showed evidence of more extensive airway remodeling, 41 in particular in airway smoothmuscle mass. Differences in remodeling may therefore provide an alternative or additional mechanism to account for disease severity in this population. References 1 Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000; 106: CHEST / 133 / 2/ FEBRUARY,

7 2 Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998; 12: Benayoun L, Druilhe A, Dombret MC, et al. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003; 167: Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: Naseer T, Minshall EM, Leung DY, et al. Expression of IL-12 and IL-13 mrna in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 1997; 155: Leung DY. Steroid-resistant asthma. West J Med 1995; 163: Li LB, Goleva E, Hall CF, et al. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/ extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 2004; 114: Hauk PJ, Goleva E, Strickland I, et al. Increased glucocorticoid receptor expression converts mouse hybridoma cells to a corticosteroid-insensitive phenotype. Am J Respir Cell Mol Biol 2002; 27: American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162: Julius SM, Sherman JM, Hendeles L. Accuracy of three electronic monitors for metered-dose inhalers. Chest 2002; 121: Lemiere C, Ernst P, Olivenstein R, et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006; 118: Juniper EF, O Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: American Thoracic Society. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children ; Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: Lemiere C, Taha R, Olivenstein R, et al. Comparison of cellular composition of induced sputum analyzed with Wright staining and immunocytochemistry. J Allergy Clin Immunol 2001; 108: Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: European Network for Understanding Mechanisms of Severe. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22: Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003; 58: Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113: Louis R, Lau LC, Bron AO, et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161: Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002; 1: Nocker RE, Schoonbrood DF, van de Graaf EA, et al. Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 1996; 109: Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: Govindaraju V, Michoud MC, Al Chalabi M, et al. Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration. Am J Physiol Cell Physiol 2006; 291:C957 C Michel O, Kips J, Duchateau J, et al. Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med 1996; 154: Corne JM, Holgate ST. Mechanisms of virus induced exacerbations of asthma. Thorax 1997; 52: Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: Thompson C, Cloutier A, Bosse Y, et al. CysLT1 receptor engagement induces activator protein-1- and NF- B-dependent IL-8 expression. Am J Respir Cell Mol Biol 2006; 35: Fukakusa M, Bergeron C, Tulic MK, et al. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN- -inducible protein 10 expression in asthmatic airway mucosa. J Allergy Clin Immunol 2005; 115: Kwon OJ, Au BT, Collins PD, et al. Inhibition of interleukin-8 expression by dexamethasone in human cultured airway epithelial cells. Immunology 1994; 81: Maggi E, Parronchi P, Manetti R, et al. Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 1992; 148: Cho SH, Stanciu LA, Holgate ST, et al. Increased interleukin-4, interleukin-5, and interferon- in airway CD4 and CD8 T cells in atopic asthma. Am J Respir Crit Care Med 2005; 171: Truyen E, Coteur L, Dilissen E, et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mrna measurement in sputum of asthma patients. Thorax 2006; 61: Litonjua AA, Sparrow D, Guevarra L et al. Serum interferon- is associated with longitudinal decline in lung function among asthmatic patients: the Normative Aging Study. Ann Allergy Immunol 2003; 90: Brightling CE, Symon FA, Holgate ST, et al. Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003; 33: Wenzel SE. Severe asthma in adults. Exp Lung Res 2005; 31(suppl 1):22 40 Stamatiou P, Hamid Q, Taha R, et al. 5-oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats. J Clin Invest 1998; 102: Pepe C, Foley S, Shannon J, et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005; 116: Original Research

Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes

Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes Catherine Lemière, MD, MSc, a Pierre Ernst, MD, b Ron Olivenstein, MD, b Yasuhiro

More information

Bronchial asthma is a chronic inflammatory disorder

Bronchial asthma is a chronic inflammatory disorder Increased Expression of the Chemoattractant Cytokines Eotaxin, Monocyte Chemotactic Protein-4, and Interleukin-16 in Induced Sputum in Asthmatic Patients* Rame A. Taha, MD; Sophie Laberge, MD; Qutayba

More information

Searching for Targets to Control Asthma

Searching for Targets to Control Asthma Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important

More information

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary

More information

Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma

Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of

More information

Phenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc

Phenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic

More information

Diagnosis and Management of Fungal Allergy Monday, 9-139

Diagnosis and Management of Fungal Allergy Monday, 9-139 Diagnosis and Management of Fungal Allergy Monday, 9-139 13-2010 Alan P. Knutsen,, MD Director, Pediatric Allergy & Immunology Director, Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies

More information

Immunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine

Immunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!

More information

Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples

Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples LETTERS TO THE EDITOR 1161 test results in allergic subjects), and reportedly tolerant patients are normally not submitted to oral food challenges. In patients with pollen allergy, IgE reactivity to foods

More information

Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis. ACCP Evidence-Based Clinical Practice Guidelines

Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis. ACCP Evidence-Based Clinical Practice Guidelines Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis ACCP Evidence-Based Clinical Practice Guidelines Christopher E. Brightling, MBBS, PhD, FCCP Objectives: Nonasthmatic eosinophilic bronchitis is

More information

Impact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma

Impact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of

More information

Current Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012

Current Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012 Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available

More information

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado

More information

Assessment of a rapid liquid based cytology method for measuring sputum cell counts

Assessment of a rapid liquid based cytology method for measuring sputum cell counts Assessment of a rapid liquid based cytology method for measuring sputum cell counts Martin MJ, Lee H, Meakin G, Green A, Simms RL, Reynolds C, Winters S*, Shaw DE, Soomro I*, Harrison TW The Asthma Centre

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5

More information

Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis

Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving

More information

Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers?

Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Disclosures: Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Stanley Fineman, MD Past-President, American College of Allergy, Asthma & Immunology Adjunct Associate

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: exhaled_nitric_oxide_measurement 2/2009 3/2018 3/2019 3/2018 Description of Procedure or Service Asthma is

More information

Current Asthma Management: Opportunities for a Nutrition-Based Intervention

Current Asthma Management: Opportunities for a Nutrition-Based Intervention Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent

More information

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype

More information

C linicians have long regarded asthma as a heterogeneous

C linicians have long regarded asthma as a heterogeneous 875 ORIGINAL ARTICLE Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids R H Green, C E Brightling,

More information

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach

More information

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What

More information

Airway Inflammation in Asthma Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan.

Airway Inflammation in Asthma Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan. REVIEW ARTICLE Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan. 2 Division of Pediatric Pulmonology, Department of Pediatrics, Chang Gung Memorial

More information

The FDA Critical Path Initiative

The FDA Critical Path Initiative The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary

More information

Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges

Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges AAAAI San Antonio Tx February 2013 Catherine Lemière MD, MSc Hôpital du

More information

RESPIRATORY CARE IN GENERAL PRACTICE

RESPIRATORY CARE IN GENERAL PRACTICE RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they

More information

Inhaled corticosteroid effects both eosinophilic and non-eosinophilic inflammation in asthmatic patients

Inhaled corticosteroid effects both eosinophilic and non-eosinophilic inflammation in asthmatic patients Research Communication Mediators of Inflammation, 13(4), 285/291 (August 2004) AIM: To determine induced sputum cell counts and interleukin-8 (IL-8), tumor necrosis factor alpha (TNF-a) and leukotriene

More information

COPD and Asthma: Similarities and differences Prof. Peter Barnes

COPD and Asthma: Similarities and differences Prof. Peter Barnes and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton

More information

10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at:

10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at: for the Diagnosis and Management of Asthma and Other Pulmonary Disorders IEHP Policy: Based on a review of the currently available literature, there is insufficient evidence to support the use of FE NO

More information

COPD or not COPD, that is the question.

COPD or not COPD, that is the question. COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP

More information

Defining Asthma: Clinical Criteria. Defining Asthma: Bronchial Hyperresponsiveness

Defining Asthma: Clinical Criteria. Defining Asthma: Bronchial Hyperresponsiveness Defining Asthma: Clinical Criteria Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine, 2nd ed. Murray, Nadel, eds.(saunders:philadelphia)

More information

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis

More information

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent

More information

Exhaled Biomarkers Asthma & COPD. AS Paul DM Seminar 30 March 07

Exhaled Biomarkers Asthma & COPD. AS Paul DM Seminar 30 March 07 Exhaled Biomarkers Asthma & COPD AS Paul DM Seminar 30 March 07 Introduction Diagnosis and course of COPD/Asthma Clinical information Pulmonary function tests Arterial blood gases Chest X-raysX No direct

More information

Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?

Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen

More information

Relationship of Small Airway Chymase-Positive Mast Cells and Lung Function in Severe. Asthma

Relationship of Small Airway Chymase-Positive Mast Cells and Lung Function in Severe. Asthma Relationship of Small Airway Chymase-Positive Mast Cells and Lung Function in Severe Asthma Silvana Balzar, M.D., Hong Wei Chu, M.D., Matthew Strand, Ph.D, Sally Wenzel, M.D. Online Data Supplement METHODS

More information

C hronic obstructive pulmonary disease (COPD) is a multicomponent

C hronic obstructive pulmonary disease (COPD) is a multicomponent 938 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial Jean Bourbeau, Pota Christodoulopoulos, Francois Maltais,

More information

E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling

E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling Ruby Pawankar, MD, Ph.D. FRCP, FAAAAI Prof. Div of Allergy, Dept of Pediatrics Nippon Medical School Tokyo, Japan pawankar.ruby@gmail.com

More information

Disclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine

Disclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Action plans, and asthma self-management, 47 51 education on, 48 49 health literacy-based education on, 49 50 Airway hyperresponsiveness, assessment

More information

Clinical Study Principal Components Analysis of Atopy-Related Traits in a Random Sample of Children

Clinical Study Principal Components Analysis of Atopy-Related Traits in a Random Sample of Children International Scholarly Research Network ISRN Allergy Volume 2011, Article ID 170989, 4 pages doi:10.5402/2011/170989 Clinical Study Principal Components Analysis of Atopy-Related Traits in a Random Sample

More information

Using Patient Characteristics to Individualize and Improve Asthma Care

Using Patient Characteristics to Individualize and Improve Asthma Care Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

COPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI

COPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis

More information

Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management

Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational

More information

BRONCHIAL THERMOPLASTY

BRONCHIAL THERMOPLASTY Review Article 155 BRONCHIAL THERMOPLASTY Prince James* and Richa Gupta* (Received on 4.5.2010; Accepted after revision on 5.9.2011) Summary: Even with the use of maximum pharmacological treatment, asthma

More information

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80) Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Small Airways Disease. Respiratory Function In Small Airways And Asthma. Pathophysiologic Changes in the Small Airways of Asthma Patients

Small Airways Disease. Respiratory Function In Small Airways And Asthma. Pathophysiologic Changes in the Small Airways of Asthma Patients Small Airways Disease Respiratory Function In Small Airways And Relevant Questions On Small Airway Involvement In How can small airway disease be defined? What is the link between small airway abnormalities

More information

Do We Need Biologics in Pediatric Asthma Management?

Do We Need Biologics in Pediatric Asthma Management? Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by

More information

Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network

Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators

More information

Differences in proteoglycan deposition in the airways of moderate and severe asthmatics

Differences in proteoglycan deposition in the airways of moderate and severe asthmatics Eur Respir J 2007; 29: 71 77 DOI: 10.1183/09031936.00047905 CopyrightßERS Journals Ltd 2007 Differences in proteoglycan deposition in the airways of moderate and severe asthmatics L. Pini*, Q. Hamid*,

More information

THE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital

THE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital THE PROMISE OF NEW AND NOVEL DRUGS Pyng Lee Respiratory & Critical Care Medicine National University Hospital Pyng_lee@nuhs.edu.sg Asthma Prevalence, Morbidity, Mortality 235 million suffer from asthma

More information

LINEE GUIDA DELL ASMA: UP TO DATE

LINEE GUIDA DELL ASMA: UP TO DATE LINEE GUIDA DELL ASMA: UP TO DATE Azienda Ospedaliera Pisana Università degli Studi di Pisa Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic and Vascular Department,

More information

Neutrophils in induced sputum arise from central airways

Neutrophils in induced sputum arise from central airways Eur Respir J 2000; 15: 36±40 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Neutrophils in induced sputum arise from central airways Y.P.

More information

I have no perceived conflicts of interest or commercial relationships to disclose.

I have no perceived conflicts of interest or commercial relationships to disclose. ASTHMA BASICS Michelle Dickens RN FNP-C AE-C Nurse Practitioner/Certified Asthma Educator Ferrell Duncan Allergy/Asthma/Immunology Coordinator, CoxHealth Asthma Center DISCLOSURES I have no perceived conflicts

More information

This is a cross-sectional analysis of the National Health and Nutrition Examination

This is a cross-sectional analysis of the National Health and Nutrition Examination SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is

More information

International Journal of Medical Research & Health Sciences

International Journal of Medical Research & Health Sciences International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:

More information

Prof Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital

Prof Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1 58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family

More information

Increased Leukotriene E 4 in the Exhaled Breath Condensate of Children With Mild Asthma*

Increased Leukotriene E 4 in the Exhaled Breath Condensate of Children With Mild Asthma* CHEST Original Research Increased Leukotriene E 4 in the Exhaled Breath Condensate of Children With Mild Asthma* Atsushi Shibata, MD; Toshio Katsunuma, MD, PhD; Morimitsu Tomikawa, MD; Aiko Tan, MD; Keisuke

More information

FVC to Slow Inspiratory Vital Capacity Ratio* A Potential Marker for Small Airways Obstruction

FVC to Slow Inspiratory Vital Capacity Ratio* A Potential Marker for Small Airways Obstruction Original Research PSYCHOLOGICAL TESTING FVC to Slow Inspiratory Vital Capacity Ratio* A Potential Marker for Small Airways Obstruction Judith Cohen, MD; Dirkje S. Postma, MD, PhD; Karin Vink-Klooster;

More information

COPYRIGHTED MATERIAL. Definition and Pathology CHAPTER 1. John Rees

COPYRIGHTED MATERIAL. Definition and Pathology CHAPTER 1. John Rees CHAPTER 1 Definition and Pathology John Rees Sherman Education Centre, Guy s Hospital, London, UK OVERVIEW Asthma is an overall descriptive term but there are a number of more or less distinct phenotypes

More information

Grass pollen immunotherapy induces Foxp3 expressing CD4 + CD25 + cells. in the nasal mucosa. Suzana Radulovic MD, Mikila R Jacobson PhD,

Grass pollen immunotherapy induces Foxp3 expressing CD4 + CD25 + cells. in the nasal mucosa. Suzana Radulovic MD, Mikila R Jacobson PhD, Radulovic 1 1 2 3 Grass pollen immunotherapy induces Foxp3 expressing CD4 + CD25 + cells in the nasal mucosa 4 5 6 7 Suzana Radulovic MD, Mikila R Jacobson PhD, Stephen R Durham MD, Kayhan T Nouri-Aria

More information

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D.

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D. Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma

More information

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma

More information

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires

More information

HCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview

HCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither

More information

Update on Biologicals for ABPA and Asthma

Update on Biologicals for ABPA and Asthma Update on Biologicals for ABPA and Asthma 5 th Advances Against Aspergillosis Istanbul 27 Jan 2012 Richard B. Moss MD Professor of Pediatrics Stanford University Palo Alto CA USA Disease of chronic airway

More information

COPD. Breathing Made Easier

COPD. Breathing Made Easier COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought

More information

Property of Presenter

Property of Presenter Have We Missed A Role For Neutrophils In Asthma? In Steroid-Refractory Asthma? Erwin W. Gelfand, MD Chairman, Department of Pediatrics National Jewish Health Professor of Pediatrics and Immunology University

More information

Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.

Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma

More information

Dr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline

Dr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline Pathology of Asthma Dr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline Bronchial Asthma Definition: chronic, relapsing inflammatory lung disorder characterised by reversible

More information

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which

More information

Induced sputum to assess airway inflammation: a study of reproducibility

Induced sputum to assess airway inflammation: a study of reproducibility Clinical and Experimental Allergy. 1997. Volume 27. pages 1138-1144 Induced sputum to assess airway inflammation: a study of reproducibility A. SPANEVELLO, G. B. MIGLIORI. A. SHARARA*, L. BALLARDlNIt,

More information

Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?

Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP? 10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher

More information

Bronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013

Bronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013 Bronchial asthma E. Cserháti 1 st Department of Paediatrics Lecture for english speaking students 5 February 2013 Epidemiology of childhood bronchial asthma Worldwide prevalence of 7-8 and 13-14 years

More information

Exhaled Nitric Oxide and Exhaled Breath Condensate ph in Severe Refractory Asthma

Exhaled Nitric Oxide and Exhaled Breath Condensate ph in Severe Refractory Asthma CHEST Exhaled Nitric Oxide and Exhaled Breath Condensate ph in Severe Refractory Asthma Original Research Eleni Tseliou, MD ; Vasiliki Bessa, MD ; Georgios Hillas, MD ; Vasiliki Delimpoura, MD ; Georgia

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes

More information

Asthma COPD Overlap (ACO)

Asthma COPD Overlap (ACO) Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma

More information

Differential diagnosis

Differential diagnosis Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between

More information

Effects of inhaled versus systemic corticosteroids on exhaled nitric oxide in severe acute asthma

Effects of inhaled versus systemic corticosteroids on exhaled nitric oxide in severe acute asthma Respiratory Medicine (2009) 103, 614e620 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Effects of inhaled versus systemic corticosteroids on exhaled nitric oxide in

More information

Medicine Dr. Kawa Lecture 1 Asthma Obstructive & Restrictive Pulmonary Diseases Obstructive Pulmonary Disease Indicate obstruction to flow of air

Medicine Dr. Kawa Lecture 1 Asthma Obstructive & Restrictive Pulmonary Diseases Obstructive Pulmonary Disease Indicate obstruction to flow of air Medicine Dr. Kawa Lecture 1 Asthma Obstructive & Restrictive Pulmonary Diseases Obstructive Pulmonary Disease Indicate obstruction to flow of air through the airways. As asthma, COPD ( chronic bronchitis

More information

Subclinical phenotypes of asthma

Subclinical phenotypes of asthma 1 Subclinical phenotypes of asthma P Bradding DM FRCP*, RH Green MD FRCP* * Institute for Lung Health and Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK Department of Infection,

More information

Biologic Therapy in the Management of Asthma. Nabeel Farooqui, MD

Biologic Therapy in the Management of Asthma. Nabeel Farooqui, MD Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal

More information

SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI IL-5 ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA

SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI IL-5 ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA FIND OUT MORE VISIT - WWW.NUCALA.CO.UK Vial not actual size

More information

APSR RESPIRATORY UPDATES

APSR RESPIRATORY UPDATES APSR RESPIRATORY UPDATES Volume 5, Issue 7 Newsletter Date: July 2013 APSR EDUCATION PUBLICATION Inside this issue: Induced sputum A large subgroup of mild-to-moderate asthma is persistently noneosinophilic

More information

Exhaled Nitric Oxide Today s Asthma Biomarker. Richard F. Lavi, MD FAAAAI FAAP

Exhaled Nitric Oxide Today s Asthma Biomarker. Richard F. Lavi, MD FAAAAI FAAP Exhaled Nitric Oxide Today s Asthma Biomarker Richard F. Lavi, MD FAAAAI FAAP Objectives Describe exhaled nitric oxide physiology and pathophysiology Review the current literature regarding exhaled nitric

More information

Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study

Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study Eur Respir J 2010; 35: 48 53 DOI: 10.1183/09031936.00130008 CopyrightßERS Journals Ltd 2010 Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study J. Chakir*, L. Loubaki*,

More information

Policy Effective 4/1/2018

Policy Effective 4/1/2018 Corporate Medical Policy Interleukin-5 Antagonists Notification File Name: Origination: Last CAP Review: Next CAP Review: Last Review: interleukin_5_antagonists 2/2016 11/2017 11/2018 2/2018 Policy Effective

More information

MEDICAL POLICY. Proprietary Information of YourCare Health Plan

MEDICAL POLICY. Proprietary Information of YourCare Health Plan MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

Bronchial Provocation Results: What Does It Mean?

Bronchial Provocation Results: What Does It Mean? Bronchial Provocation Results: What Does It Mean? Greg King 1 Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards 2065 2 Woolcock Institute of Medical Research and Sydney Medical

More information

West of Scotland Difficult Asthma Group Statement of Practice

West of Scotland Difficult Asthma Group Statement of Practice West of Scotland Difficult Asthma Group Statement of Practice Member Health Boards: Ayrshire and Arran Dumfries and Galloway Forth Valley Lanarkshire Glasgow INFORMATION ON THE USE OF BRONCHIAL THERMOPLASTY

More information

ASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009

ASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009 This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp ASTHMA CARE FOR CHILDREN

More information

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective

More information

Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma

Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma Original Article Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma Feng-Jia Chen, Huai Liao, Xin-Yan Huang, Can-Mao Xie Department of Respiratory

More information

Defining Asthma: Clinical Criteria. Defining Asthma: Bronchial Hyperresponsiveness

Defining Asthma: Clinical Criteria. Defining Asthma: Bronchial Hyperresponsiveness Defining Asthma: Clinical Criteria Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine, 2nd ed. Murray, Nadel, eds.(saunders:philadelphia)

More information

Defining Asthma: Bronchial Hyperresponsiveness. Defining Asthma: Clinical Criteria. Impaired Ventilation in Asthma. Dynamic Imaging of Asthma

Defining Asthma: Bronchial Hyperresponsiveness. Defining Asthma: Clinical Criteria. Impaired Ventilation in Asthma. Dynamic Imaging of Asthma Defining Asthma: Clinical Criteria Defining Asthma: Bronchial Hyperresponsiveness Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine,

More information